| Name | Deucravacitinib |
| Description | Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor for the treatment of autoimmune diseases. It blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain, inhibiting IL-12/23 and type I IFN pathways. It selectively binds to the TYK2 pseudokinase (JH2) domain with an IC50 of 1.0 nM. |
| In vitro | METHODS: The mean daily percent inhibition of TYK2 was simulated by Deucravacitinib (BMS-986165) (6 mg/12 mg once daily) at clinically relevant concentrations.
RESULTS Deucravacitinib (BMS-986165) had minimal effects on IL-2-induced STAT5 phosphorylation (JAK 1/3) and TPO-induced STAT3 phosphorylation (JAK 2/2). [3] |
| In vivo | METHODS: When mirdametinib was used in combination with Deucravacitinib (BMS-986165) (40 μM) in JW23.3 cells, cell growth was observed.
RESULTS Both drugs synergistically inhibited cell proliferation and increased cell apoptosis compared to either drug alone. [4] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 84.2 mg/mL (197.9 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween-80+45% Saline : 3.3 mg/mL (7.76 mM), Sonication is recommended.
|
| Keywords | TyrosineKinases | Tyrosine Kinases | Tyk2 JH2 | Janus kinase | JAK1-JH2 | JAK1 JH2 | JAK | Interleukin Related | Interleukin | Interferon-α/β receptor | Interferon-alpha/beta receptor | Inhibitor | inhibit | IFNAR | Deucravacitinib | BMS986165 | BMS 986165 |
| Inhibitors Related | Kaolin | Undecane | Fluorene | Ethyl palmitate | Rhamnose monohydrate | D(+)-Raffinose pentahydrate | Hydroxypropyl Cellulose | 1,8-Cineole | Tributyrin | Gluconate Calcium | Gefitinib | Magnesium sulfate |
| Related Compound Libraries | Highly Selective Inhibitor Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Tyrosine Kinase Inhibitor Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Kinase Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
